BioWorld

Dec. 4, 2006

As Pfizer Changes, Biotech Partners Seem Unaffected

A loss of exclusivity, strong competition and a changing market led Pfizer Inc. to cut its U.S. sales force by 20 percent last week, yet analysts say the move should have little impact - if any - on the biotech community. (BioWorld Today) Read More

House Committee To Take Up Uncertainties Around EPO Use

Will 2007 Have Tidings Of Joy? Some Thoughts On Next Year

Cousin Of Singulair, Is Celebrex Useful In Cardiac Hypertrophy?

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...